{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T20:45:52Z","timestamp":1780778752944,"version":"3.54.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Engineering probiotics have emerged as a potential strategy for the treatment of metabolic diseases. However, due to the exceptional complexity of these metabolic disorders and the intricate relationship between gut microbes, it is difficult to achieve an ideal therapeutic effect in a specific metabolic disorder using only a single engineered strain. In this work, we proposed a probiotic cocktail strategy by engineering two cascade metabolic bacteria to treat hyperlysinemia, an inherited lysine metabolic disorder with loss of \u03b1-aminoadipate semialdehyde synthase (AASS) activity. A probiotic <jats:italic>E. coli<\/jats:italic> Nissle 1917 strain <jats:italic>EcNT (pTLS)<\/jats:italic> with a heterologous enzyme pathway in Saccharomyces cerevisiae was engineered to metabolize the excess lysine. Another one <jats:italic>EcNT (pK25)<\/jats:italic> was engineered to consume the products of lysine metabolism. The bacterial cocktail enables the maintenance of a metabolic cascade with AASS-like functional activity to maintain the blood lysine concentrations and downstream metabolites. <jats:italic>In vitro<\/jats:italic> experimental results showed that the cocktail bacteria had a better metabolic capacity and metabolites balance at a ratio of <jats:italic>EcNT (pTLS)<\/jats:italic> and <jats:italic>EcNT (pK25)<\/jats:italic> of 1:2. Feeding of the cocktail bacteria to the mouse model effectively reduced the concentration of lysine and balanced saccharopine in the plasma of hyperlysinemia-like mice. These findings not only provide a promising strategy of probiotic stains for the treatment of hyperlysinemia but also highlight the potential of engineered cascade cocktails to intervene and even cure other inherited metabolic diseases.<\/jats:p>","DOI":"10.3389\/fmicb.2024.1366017","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T06:54:39Z","timestamp":1717052079000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Engineered probiotic cocktail with two cascade metabolic Escherichia coli for the treatment of hyperlysinemia"],"prefix":"10.3389","volume":"15","author":[{"given":"Feng","family":"Geng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"L\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.1038\/s41467-021-26524-0","article-title":"Improvement of a synthetic live bacterial therapeutic for phenylketonuria with biosensor-enabled enzyme engineering","volume":"12","author":"Adolfsen","year":"2021","journal-title":"Nat. Commun."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-020-15508-1","article-title":"Developing a new class of engineered live bacterial therapeutics to treat human diseases","volume":"11","author":"Charbonneau","year":"2020","journal-title":"Nat. Commun."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41573-021-00285-3","article-title":"Engineering living therapeutics with synthetic biology","volume":"20","author":"Cubillos-Ruiz","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.febslet.2012.02.023","article-title":"Lysine degradation through the saccharopine pathway in bacteria: LKR and SDH in bacteria and its relationship to the plant and animal enzymes","volume":"586","author":"de Mello Serrano","year":"2012","journal-title":"FEBS Lett."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut microbiota in human metabolic health and disease","volume":"19","author":"Fan","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-3-642-15720-2_23","article-title":"Cerebral organic acid disorders and other disorders of lysine catabolism","volume-title":"Inborn metabolic diseases: Diagnosis and treatment","author":"Hoffmann","year":"2012"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1093\/hmg\/ddu218","article-title":"Mitochondrial NADP(H) deficiency due to a mutation in NADK2 causes dienoyl-CoA reductase deficiency with hyperlysinemia","volume":"23","author":"Houten","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1750-1172-8-57","article-title":"Genetic basis of hyperlysinemia","volume":"8","author":"Houten","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nbt.4222","article-title":"Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria","volume":"36","author":"Isabella","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10529-018-2514-7","article-title":"Enhancement of the thermal and alkaline pH stability of Escherichia coli lysine decarboxylase for efficient cadaverine production","volume":"40","author":"Kou","year":"2018","journal-title":"Biotechnol. Lett."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"887019","DOI":"10.3389\/fnut.2022.887019","article-title":"The use of probiotic therapy in metabolic and neurological diseases","volume":"9","author":"Lee","year":"2022","journal-title":"Front. Nutr."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ymben.2015.06.006","article-title":"Metabolic engineering of Escherichia coli using CRISPR\u2013Cas9 meditated genome editing","volume":"31","author":"Li","year":"2015","journal-title":"Metab. Eng."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12934-022-01799-0","article-title":"Engineered probiotics","volume":"21","author":"Ma","year":"2022","journal-title":"Microb. Cell Fact."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1038\/s41467-019-13336-6","article-title":"Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut","volume":"10","author":"Praveschotinunt","year":"2019","journal-title":"Nat. Commun."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s42255-021-00430-7","article-title":"Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1\/2a study","volume":"3","author":"Puurunen","year":"2021","journal-title":"Nat. Metab."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1086\/302919","article-title":"Identification of the alpha-aminoadipic semialdehyde synthase gene, which is defective in familial hyperlysinemia","volume":"66","author":"Sacksteder","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41591-021-01390-x","article-title":"Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease","volume":"27","author":"Scott","year":"2021","journal-title":"Nat. Med."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/bab.1822","article-title":"Efficient engineered probiotics using synthetic biology approaches: a review","volume":"67","author":"Yadav","year":"2020","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1039\/D2TB00300G","article-title":"Oral nanozyme-engineered probiotics for the treatment of ulcerative colitis","volume":"10","author":"Zhao","year":"2022","journal-title":"J. Mater. Chem. B"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s41551-020-0582-1","article-title":"An orally delivered microbial cocktail for the removal of nitrogenous metabolic waste in animal models of kidney failure","volume":"4","author":"Zheng","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1083\/jcb.201807204","article-title":"The lysine catabolite saccharopine impairs development by disrupting mitochondrial homeostasis","volume":"218","author":"Zhou","year":"2019","journal-title":"J. Cell Biol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1366017\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T06:54:42Z","timestamp":1717052082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1366017\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":21,"alternative-id":["10.3389\/fmicb.2024.1366017"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2024.1366017","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"article-number":"1366017"}}